% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
%
\documentclass[
]{article}
\usepackage{amsmath,amssymb}
\usepackage{iftex}
\ifPDFTeX
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math} % this also loads fontspec
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
\fi
\usepackage{lmodern}
\ifPDFTeX\else
  % xetex/luatex font selection
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\makeatletter
\@ifundefined{KOMAClassName}{% if non-KOMA class
  \IfFileExists{parskip.sty}{%
    \usepackage{parskip}
  }{% else
    \setlength{\parindent}{0pt}
    \setlength{\parskip}{6pt plus 2pt minus 1pt}}
}{% if KOMA class
  \KOMAoptions{parskip=half}}
\makeatother
\usepackage{xcolor}
\usepackage[margin=1in]{geometry}
\usepackage{color}
\usepackage{fancyvrb}
\newcommand{\VerbBar}{|}
\newcommand{\VERB}{\Verb[commandchars=\\\{\}]}
\DefineVerbatimEnvironment{Highlighting}{Verbatim}{commandchars=\\\{\}}
% Add ',fontsize=\small' for more characters per line
\usepackage{framed}
\definecolor{shadecolor}{RGB}{248,248,248}
\newenvironment{Shaded}{\begin{snugshade}}{\end{snugshade}}
\newcommand{\AlertTok}[1]{\textcolor[rgb]{0.94,0.16,0.16}{#1}}
\newcommand{\AnnotationTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{\textbf{\textit{#1}}}}
\newcommand{\AttributeTok}[1]{\textcolor[rgb]{0.13,0.29,0.53}{#1}}
\newcommand{\BaseNTok}[1]{\textcolor[rgb]{0.00,0.00,0.81}{#1}}
\newcommand{\BuiltInTok}[1]{#1}
\newcommand{\CharTok}[1]{\textcolor[rgb]{0.31,0.60,0.02}{#1}}
\newcommand{\CommentTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{\textit{#1}}}
\newcommand{\CommentVarTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{\textbf{\textit{#1}}}}
\newcommand{\ConstantTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{#1}}
\newcommand{\ControlFlowTok}[1]{\textcolor[rgb]{0.13,0.29,0.53}{\textbf{#1}}}
\newcommand{\DataTypeTok}[1]{\textcolor[rgb]{0.13,0.29,0.53}{#1}}
\newcommand{\DecValTok}[1]{\textcolor[rgb]{0.00,0.00,0.81}{#1}}
\newcommand{\DocumentationTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{\textbf{\textit{#1}}}}
\newcommand{\ErrorTok}[1]{\textcolor[rgb]{0.64,0.00,0.00}{\textbf{#1}}}
\newcommand{\ExtensionTok}[1]{#1}
\newcommand{\FloatTok}[1]{\textcolor[rgb]{0.00,0.00,0.81}{#1}}
\newcommand{\FunctionTok}[1]{\textcolor[rgb]{0.13,0.29,0.53}{\textbf{#1}}}
\newcommand{\ImportTok}[1]{#1}
\newcommand{\InformationTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{\textbf{\textit{#1}}}}
\newcommand{\KeywordTok}[1]{\textcolor[rgb]{0.13,0.29,0.53}{\textbf{#1}}}
\newcommand{\NormalTok}[1]{#1}
\newcommand{\OperatorTok}[1]{\textcolor[rgb]{0.81,0.36,0.00}{\textbf{#1}}}
\newcommand{\OtherTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{#1}}
\newcommand{\PreprocessorTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{\textit{#1}}}
\newcommand{\RegionMarkerTok}[1]{#1}
\newcommand{\SpecialCharTok}[1]{\textcolor[rgb]{0.81,0.36,0.00}{\textbf{#1}}}
\newcommand{\SpecialStringTok}[1]{\textcolor[rgb]{0.31,0.60,0.02}{#1}}
\newcommand{\StringTok}[1]{\textcolor[rgb]{0.31,0.60,0.02}{#1}}
\newcommand{\VariableTok}[1]{\textcolor[rgb]{0.00,0.00,0.00}{#1}}
\newcommand{\VerbatimStringTok}[1]{\textcolor[rgb]{0.31,0.60,0.02}{#1}}
\newcommand{\WarningTok}[1]{\textcolor[rgb]{0.56,0.35,0.01}{\textbf{\textit{#1}}}}
\usepackage{graphicx}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
% Set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother
\setlength{\emergencystretch}{3em} % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{-\maxdimen} % remove section numbering
\ifLuaTeX
  \usepackage{selnolig}  % disable illegal ligatures
\fi
\IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}}
\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\urlstyle{same}
\hypersetup{
  pdftitle={Desing chimeras},
  pdfauthor={Alberto Santiago},
  hidelinks,
  pdfcreator={LaTeX via pandoc}}

\title{Desing chimeras}
\author{Alberto Santiago}
\date{2023-11-02}

\begin{document}
\maketitle

\hypertarget{data-driven-design-of-compounds-against-trichomonas-vaginalis}{%
\subsection{Data-driven design of compounds against Trichomonas
vaginalis}\label{data-driven-design-of-compounds-against-trichomonas-vaginalis}}

Abstract: Trichomoniasis is a sexually transmitted disease caused by the
protozoan parasite Trichomonas vaginalis, which affects 3.9\% of the
world's population. Metronidazole is the most common compound used to
treat this infection, which causes breaks in the parasite's DNA strand,
inhibiting its synthesis and viability. Nevertheless, in recent years,
the parasite has shown resistance to metronidazole, so searching for new
compounds against such a pathogen becomes necessary. Therefore, in the
present work, we performed a computer-assisted drug design approach
searching for molecules that could act against trichomoniasis. Firstly,
we developed a screening analysis based on molecular descriptors (1-4D).
Then resulting molecules were processed by molecular docking analysis to
identify those with better interaction with the active site of the
protein TvMP50 (a virulence factor of the parasite involved in its
cytotoxicity toward the host cell). Finally, fragments of the most
active molecules were generated and assembled into new chimeric
molecular entities, which then were reevaluated against the mentioned
protein. As results, we obtained a database of compounds that could be
considered in the design of novel compounds against T. vaginalis from
which we obtain a new molecule derived from
Emodin-Lucidin-Isopropyl-Ether (ELIE) that presented an optimal activity
(ΔG=-17.0 kcal/mol) and could be consider for further studies.

\hypertarget{molecular-descriptors.}{%
\subsubsection{Molecular descriptors.}\label{molecular-descriptors.}}

Molecular descriptors are numerical values that are used to describe
different characteristics of molecules, such as physicochemical,
topological, and three-dimensional structural properties, and are
usually analyzed in 3 dimensions. Although there are thousands of
molecular descriptors, the most frequently used include molecular weight
(MW), octanol/water partition coefficient (SlogP), topological polar
surface area (TPSA), hydrogen bond donors (HBD), hydrogen bond acceptors
(HBA), number of rotating bonds (RB), electronic or charge distribution,
preferred conformations, heats of formation, solubility, LogP, pKa,
refractivity, melting point, molecule length, molecular area, molecular
volume, and reactive groups.

In this study, we analyzed Lipinski's rules, which suggest that there is
better absorption or permeation when there are 5 hydrogen bond donors or
less, 10 hydrogen bond acceptors or less, a molecular weight (MW) of 500
Daltons or less, and a Log P of 5 or less. According to Lipinski's rule,
in general, an active substance for oral administration should not
violate more than one rule.

In this study, we calculated the molecular descriptors of a set of
molecules identified by mesh filtering in the PubMed database. There
were 34 filtered compounds. The molecular descriptors were calculated
using three different software/platforms: DataWarrior, Drulito, and
SwissADME.

\begin{Shaded}
\begin{Highlighting}[]
\NormalTok{Des\_Mol\_Total }\OtherTok{\textless{}{-}} \FunctionTok{read.csv}\NormalTok{(}\StringTok{"/cloud/project/DT\_Dru\_Swiss\_des\_mol\_total.csv"}\NormalTok{, }\AttributeTok{header=}\NormalTok{T)}


\NormalTok{DF\_Des\_Mol\_2 }\OtherTok{\textless{}{-}} \FunctionTok{data.frame}\NormalTok{(Des\_Mol\_Total)}


\FunctionTok{head}\NormalTok{(DF\_Des\_Mol\_2)}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
##             Name
## 1    2H-chromene
## 2 Betulinic acid
## 3      Nectandra
## 4   Caffeic acid
## 5      Candimine
## 6 Carmaphycin-17
##                                                                                                Smiles
## 1                                                                                   C1Oc(cccc2)c2C=C1
## 2                             CC(C)(C(CC1)C(C)(CC2)C(CC3)C1(C)C(C)(CC1)C3C(C(CC3)C(C)=C)C13C(O)=O)C2O
## 3                                                                        CC(CCC=C(C)C)(C1CC=C(C)CC1)O
## 4                                                                             OC(C=Cc(cc1)cc(O)c1O)=O
## 5                                                       CN(CC1)C(C(C2OC(c3c4OC)=O)c3cc3c4OCO3)C1=CC2O
## 6 CCCCCC(N[C@H](Cc1c[nH]c2c1cccc2)C(NC(Cc1c[nH]c2c1cccc2)C(N[C@H](Cc1ccccc1)C([C@]1(C)OC1)=O)=O)=O)=O
##   Total.Molweight  cLogP  cLogS H.Acceptors H.Donors Total.Surface.Area
## 1         132.160 20.636 -2.388           1        0             110.02
## 2         456.708 63.706 -6.278           3        2             337.41
## 3         222.370 44.711 -3.162           1        1             196.52
## 4         180.159  0.783 -1.407           4        3             136.56
## 5         345.350 15.068 -3.051           7        1             234.17
## 6         675.827 44.372 -6.830          10        5             533.16
##   Relative.PSA Polar.Surface.Area Druglikeness Mutagenic Tumorigenic
## 1     0.090893               9.23      -19.351      none        none
## 2     0.116300              57.53      -21.490      none        none
## 3     0.066660              20.23      -14.665      none        none
## 4     0.383270              77.76        0.168      none        none
## 5     0.297600              77.46       50.872       low        none
## 6     0.247900             148.48      -72.848      high        high
##   Reproductive.Effective Irritant Molecular.Flexibility     MW  logP  AlogP HBA
## 1                   none     none               0.13010 123.99 1.475  1.086   1
## 2                   none     none               0.36111 407.98 9.407  2.350   3
## 3                   none     high               0.65996 195.99 4.085  2.750   1
## 4                   none     none               0.39892 171.98 0.888  0.203   4
## 5                   none     none               0.19800 325.97 0.236 -1.036   7
## 6                   none     high               0.46390 629.99 3.575 -1.827  10
##   HBD  TPSA    AMR nRB nAtom nAcidicGroup RC nRigidB nAromRing nHB Salerts
## 1   0  9.23  45.71   0    10            0  2      11         1   1       0
## 2   0 17.07 131.75   2    33            0  5      35         0   3       0
## 3   0  0.00  71.19   4    16            0  1      12         0   1       0
## 4   0 17.07  50.41   2    13            0  1      11         1   4       1
## 5   0 57.23  90.00   1    25            0  5      28         1   7       2
## 6   0 80.81 196.93  20    50            0  6      35         5  10       2
##      Formula   MW.1 X.Heavy.atoms X.Aromatic.heavy.atoms Fraction.Csp3
## 1      C9H8O 132.16            10                      6          0.11
## 2   C30H48O3 456.70            33                      0          0.90
## 3    C15H26O 222.37            16                      0          0.73
## 4     C9H8O4 180.16            13                      6          0.00
## 5  C18H19NO6 345.35            25                      6          0.50
## 6 C40H45N5O5 675.82            50                     24          0.35
##   X.Rotatable.bonds X.H.bond.acceptors X.H.bond.donors     MR TPSA.1 iLOGP
## 1                 0                  1               0  40.91   9.23  2.04
## 2                 2                  3               2 136.91  57.53  3.79
## 3                 4                  1               1  72.36  20.23  3.46
## 4                 2                  4               3  47.16  77.76  0.97
## 5                 1                  7               1  90.05  77.46  2.59
## 6                20                  5               5 194.03 148.48  4.41
##   XLOGP3 WLOGP MLOGP Silicos.IT.Log.P Consensus.Log.P ESOL.Log.S
## 1   2.25  1.98  1.97             2.44            2.14      -2.52
## 2   8.21  7.09  5.82             5.75            6.13      -7.71
## 3   3.79  4.23  3.56             3.74            3.76      -3.34
## 4   1.15  1.09  0.70             0.75            0.93      -1.89
## 5   0.69  0.67  1.21             1.16            1.26      -2.53
## 6   6.00  5.07  1.79             8.36            5.13      -6.85
##   ESOL.Solubility..mg.ml. ESOL.Solubility..mol.l.     ESOL.Class Ali.Log.S
## 1                3.98e-01                3.01e-03        Soluble     -2.08
## 2                8.87e-06                1.94e-08 Poorly soluble     -9.28
## 3                1.01e-01                4.55e-04        Soluble     -3.91
## 4                2.32e+00                1.29e-02   Very soluble     -2.38
## 5                1.03e+00                2.97e-03        Soluble     -1.89
## 6                9.65e-05                1.43e-07 Poorly soluble     -8.90
##   Ali.Solubility..mg.ml. Ali.Solubility..mol.l.      Ali.Class Silicos.IT.LogSw
## 1               1.10e+00               8.32e-03        Soluble            -2.46
## 2               2.40e-07               5.26e-10 Poorly soluble            -5.70
## 3               2.74e-02               1.23e-04        Soluble            -3.00
## 4               7.55e-01               4.19e-03        Soluble            -0.71
## 5               4.41e+00               1.28e-02   Very soluble            -2.34
## 6               8.60e-07               1.27e-09 Poorly soluble           -12.78
##   Silicos.IT.Solubility..mg.ml. Silicos.IT.Solubility..mol.l.
## 1                      4.54e-01                      3.44e-03
## 2                      9.09e-04                      1.99e-06
## 3                      2.24e-01                      1.01e-03
## 4                      3.51e+01                      1.95e-01
## 5                      1.58e+00                      4.58e-03
## 6                      1.13e-10                      1.67e-13
##     Silicos.IT.class GI.absorption BBB.permeant Pgp.substrate CYP1A2.inhibitor
## 1            Soluble          High          Yes            No              Yes
## 2 Moderately soluble           Low           No            No               No
## 3            Soluble          High          Yes            No               No
## 4            Soluble          High           No            No               No
## 5            Soluble          High           No            No               No
## 6          Insoluble           Low           No           Yes              Yes
##   CYP2C19.inhibitor CYP2C9.inhibitor CYP2D6.inhibitor CYP3A4.inhibitor
## 1                No               No               No               No
## 2                No              Yes               No               No
## 3                No              Yes               No               No
## 4                No               No               No               No
## 5                No               No              Yes               No
## 6               Yes              Yes               No              Yes
##   log.Kp..cm.s. Lipinski..violations Ghose..violations Veber..violations
## 1         -5.51                    0                 2                 0
## 2         -3.26                    1                 3                 0
## 3         -4.97                    0                 0                 0
## 4         -6.58                    0                 0                 0
## 5         -7.92                    0                 0                 0
## 6         -6.16                    1                 3                 2
##   Egan..violations Muegge..violations Bioavailability.Score PAINS..alerts
## 1                0                  2                  0.55             0
## 2                1                  1                  0.85             0
## 3                0                  1                  0.55             0
## 4                0                  1                  0.56             1
## 5                0                  0                  0.55             0
## 6                1                  3                  0.55             0
##   Brenk..alerts Leadlikeness..violations Synthetic.Accessibility
## 1             0                        1                    2.55
## 2             1                        2                    5.63
## 3             1                        2                    3.95
## 4             2                        1                    1.81
## 5             1                        0                    4.56
## 6             1                        3                    5.58
\end{verbatim}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Des\_Mol\_2, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ MW, }\AttributeTok{fill =}\NormalTok{  MW))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-1-1.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Des\_Mol\_2, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ H.Acceptors, }\AttributeTok{fill =}\NormalTok{  H.Acceptors))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-1-2.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Des\_Mol\_2, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ H.Donors, }\AttributeTok{fill =}\NormalTok{  H.Donors))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-1-3.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Des\_Mol\_2, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ logP, }\AttributeTok{fill =}\NormalTok{ logP))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-1-4.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Des\_Mol\_2, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ TPSA, }\AttributeTok{fill =}\NormalTok{  TPSA))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-1-5.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Des\_Mol\_2, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ Druglikeness, }\AttributeTok{fill =}\NormalTok{ Druglikeness))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-1-6.pdf}

\hypertarget{filtering-by-means-of-drulito}{%
\subsubsection{Filtering by means of
DruLiTo}\label{filtering-by-means-of-drulito}}

Graph of the compounds that comply and do not comply with Lipinski's
rules. A graph showing those compounds that comply with Lipinski's rules
(green star) and those that do not comply with the 5 or Lipinski's rules
(red star) is shown. This analysis was performed with Drulito software.

\url{https://niper.gov.in/pi_dev_tools/DruLiToWeb/DruLiTo_index.html}

\hypertarget{molecular-docking-screening}{%
\subsubsection{Molecular docking
screening}\label{molecular-docking-screening}}

Once the compounds that passed the Lipinski rules were obtained, their
binding interactions toward TvMP50 were evaluated by Molecular Docking.
In this step, we used the SwissDock server
(\url{http://www.swissdock.ch}), a web server that predicts the binding
modes between different targets and ligands following the methodology
cited by Grosdidier. All compounds from the initial library that
interacted with the active site of TvMP50 were accommodated in a
library, which we call the secondary chemical library.

\hypertarget{fragment-generation}{%
\subsubsection{Fragment Generation}\label{fragment-generation}}

Six leading compounds were obtained by Ghose filtering and rules of
threes, from which 4 different scaffolds were obtained.

\begin{itemize}
\tightlist
\item
  Leading compounds
\end{itemize}

Figure 1. Schematic of the chemical structures of the compounds that
satisfy the leader rule. a) Lycorine, b) Lucidin-isopropyl-ether, c)
Emodin, d) Fumagiline, e) Quercetin and f) Wogonin.

\begin{itemize}
\tightlist
\item
  Scaffolds
\end{itemize}

Figure 2. Schematic of the chemical structures of the scaffolds. a)
Ly-corine scaffolds, b) Lucidin-isopropyl-ether scaffolds, c) Emodin
scaffolds, d) Fumagiline scaffolds, e) Quercetin scaffolds and f)
Wogonin scaffolds.

Figure 3. The representation of the chimeric proposal of construction
performed by DataWarrior software. Proposed construction between Emodin
and Lucidin-isopropyl ether.

\begin{Shaded}
\begin{Highlighting}[]
\NormalTok{Quimeras }\OtherTok{\textless{}{-}} \FunctionTok{read.csv}\NormalTok{(}\StringTok{"/cloud/project/Quimeras\_des\_mol\_total.csv"}\NormalTok{, }\AttributeTok{header=}\NormalTok{T)}

\FunctionTok{head}\NormalTok{(Quimeras)}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
##                                      Name Total.Molweight Molweight
## 1                Quimera1_Emodin_Wogonine         350.369   350.369
## 2                Quimera2_Emodin_Lycorine         345.350   345.350
## 3                    Quimera3_Emodin_ATZ2         475.274   475.274
## 4               Quimera4_Emodin_Quercetin         296.277   296.277
## 5 Quimera5_Emodin_Lucidin_isopropyl_ether         342.346   342.346
## 6   Quimera6_Lucidin_isopropyl_ether_ATZ1         531.382   531.382
##   Monoisotopic.Mass   cLogP  cLogS H.Acceptors H.Donors Total.Surface.Area
## 1          350.1154  3.5726 -3.430           5        3             253.90
## 2          345.1212  1.1025 -3.007           7        3             222.69
## 3          473.9521  4.0054 -6.546           8        4             288.63
## 4          296.0685  2.0014 -3.255           5        3             211.04
## 5          342.1103 -0.2196 -4.876           6        3             249.47
## 6          530.0147  4.9473 -7.532           8        3             343.06
##   Relative.PSA Polar.Surface.Area Druglikeness Mutagenic Tumorigenic
## 1      0.23356              79.15      0.75404      none        none
## 2      0.34079              99.46      4.85430      none        none
## 3      0.41995             165.06     -0.98282      none        none
## 4      0.30980              94.83      0.98909      none        none
## 5      0.31162             109.72     -1.50060      none        none
## 6      0.34428             154.06     -1.36840       low        none
##   Reproductive.Effective Irritant     MW   logP  AlogP HBA HBD  TPSA    AMR nRB
## 1                   high     none 331.97  2.936  0.960   5   0 18.46 108.76   2
## 2                   none     none 325.97 -0.296 -1.437   7   0 38.77  90.04   0
## 3                   none     high 462.87  0.556  0.756   8   0 88.87 114.60   3
## 4                   high     none 283.97  1.218  0.615   5   0 34.14  87.07   1
## 5                   none     high 323.97  0.852 -1.388   6   0 89.49  92.57   3
## 6                   none     high 510.87  1.394  1.033   8   0 98.10 133.30   6
##   nAtom nAcidicGroup RC nRigidB nAromRing nHB Salerts
## 1    26            0  4      27         2   5       1
## 2    25            0  5      29         1   7       0
## 3    29            0  4      29         3   8       0
## 4    22            0  3      23         2   5       0
## 5    25            0  3      24         2   6       0
## 6    33            0  4      30         3   8       0
\end{verbatim}

\begin{Shaded}
\begin{Highlighting}[]
\NormalTok{DF\_Quimeras\_des }\OtherTok{\textless{}{-}} \FunctionTok{data.frame}\NormalTok{(Quimeras)}

\NormalTok{DF\_Q }\OtherTok{\textless{}{-}}\NormalTok{ DF\_Quimeras\_des }\SpecialCharTok{\%\textgreater{}\%} 
  \FunctionTok{mutate\_if}\NormalTok{(is.numeric, scale)}

\FunctionTok{head}\NormalTok{(DF\_Quimeras\_des)}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
##                                      Name Total.Molweight Molweight
## 1                Quimera1_Emodin_Wogonine         350.369   350.369
## 2                Quimera2_Emodin_Lycorine         345.350   345.350
## 3                    Quimera3_Emodin_ATZ2         475.274   475.274
## 4               Quimera4_Emodin_Quercetin         296.277   296.277
## 5 Quimera5_Emodin_Lucidin_isopropyl_ether         342.346   342.346
## 6   Quimera6_Lucidin_isopropyl_ether_ATZ1         531.382   531.382
##   Monoisotopic.Mass   cLogP  cLogS H.Acceptors H.Donors Total.Surface.Area
## 1          350.1154  3.5726 -3.430           5        3             253.90
## 2          345.1212  1.1025 -3.007           7        3             222.69
## 3          473.9521  4.0054 -6.546           8        4             288.63
## 4          296.0685  2.0014 -3.255           5        3             211.04
## 5          342.1103 -0.2196 -4.876           6        3             249.47
## 6          530.0147  4.9473 -7.532           8        3             343.06
##   Relative.PSA Polar.Surface.Area Druglikeness Mutagenic Tumorigenic
## 1      0.23356              79.15      0.75404      none        none
## 2      0.34079              99.46      4.85430      none        none
## 3      0.41995             165.06     -0.98282      none        none
## 4      0.30980              94.83      0.98909      none        none
## 5      0.31162             109.72     -1.50060      none        none
## 6      0.34428             154.06     -1.36840       low        none
##   Reproductive.Effective Irritant     MW   logP  AlogP HBA HBD  TPSA    AMR nRB
## 1                   high     none 331.97  2.936  0.960   5   0 18.46 108.76   2
## 2                   none     none 325.97 -0.296 -1.437   7   0 38.77  90.04   0
## 3                   none     high 462.87  0.556  0.756   8   0 88.87 114.60   3
## 4                   high     none 283.97  1.218  0.615   5   0 34.14  87.07   1
## 5                   none     high 323.97  0.852 -1.388   6   0 89.49  92.57   3
## 6                   none     high 510.87  1.394  1.033   8   0 98.10 133.30   6
##   nAtom nAcidicGroup RC nRigidB nAromRing nHB Salerts
## 1    26            0  4      27         2   5       1
## 2    25            0  5      29         1   7       0
## 3    29            0  4      29         3   8       0
## 4    22            0  3      23         2   5       0
## 5    25            0  3      24         2   6       0
## 6    33            0  4      30         3   8       0
\end{verbatim}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Quimeras\_des, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ Druglikeness, }\AttributeTok{fill =}\NormalTok{ Druglikeness))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
## Warning: Removed 2 rows containing missing values (`position_stack()`).
\end{verbatim}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-2-1.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Quimeras\_des, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ H.Acceptors, }\AttributeTok{fill =}\NormalTok{  H.Acceptors))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
## Warning: Removed 2 rows containing missing values (`position_stack()`).
\end{verbatim}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-2-2.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Quimeras\_des, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ H.Donors, }\AttributeTok{fill =}\NormalTok{  H.Donors))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
## Warning: Removed 2 rows containing missing values (`position_stack()`).
\end{verbatim}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-2-3.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Quimeras\_des, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ cLogP, }\AttributeTok{fill =}\NormalTok{  cLogP))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
## Warning: Removed 2 rows containing missing values (`position_stack()`).
\end{verbatim}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-2-4.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Quimeras\_des, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ Tumorigenic, }\AttributeTok{fill =}\NormalTok{  Tumorigenic))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-2-5.pdf}

\begin{Shaded}
\begin{Highlighting}[]
\FunctionTok{ggplot}\NormalTok{(DF\_Quimeras\_des, }\FunctionTok{aes}\NormalTok{(}\AttributeTok{y =}\NormalTok{ Name, }\AttributeTok{x =}\NormalTok{ TPSA, }\AttributeTok{fill =}\NormalTok{  TPSA))}\SpecialCharTok{+}
  \FunctionTok{geom\_col}\NormalTok{()}
\end{Highlighting}
\end{Shaded}

\begin{verbatim}
## Warning: Removed 1 rows containing missing values (`position_stack()`).
\end{verbatim}

\includegraphics{Proyect_TvMP50_files/figure-latex/unnamed-chunk-2-6.pdf}

\hypertarget{chimera-trichomonicidal-activity}{%
\subsubsection{Chimera Trichomonicidal
Activity}\label{chimera-trichomonicidal-activity}}

The chimaera that presented the most optimal coupling with TvMP50 was
the Emodin-Lucidin isopropyl ether chimaera that obtained a ΔG of -17.00
We visualized our results using Chimera and Discovery Studio software.

Figure 4. A schematic representation of the interaction of the ELIE
chimera that presented optimal molecular docking with a ΔG value of -17
is observed. A) Tube and rod image. B) Interaction of the amino acids of
the active site of TvMP50 with the functional groups of the
Emodin-Lucidin iso-propyl ether chimera. The aminoacids Hsp 324, Phe
201, as well as the two Zn cofactors are observed interacting with the
Emodin-Lucidin isopropyl ether chimera.

\hypertarget{discussion}{%
\subsubsection{Discussion}\label{discussion}}

The T. vaginalis parasite is exposed to different metal cations during
infection that can cause DNA damage. However, the presence of Zn2+
activates the metalloproteinase TvMP50, involved in the cytotoxicity of
the parasite. The parasite is highly resistant to the drugs used for its
treatment, so we proposed a chemoinformatics methodology to design a
chemical library of compounds with hypothetical trichomonicidal
activity. For this purpose, databases were filtered, molecular
descriptors were calculated, compounds were fragmented, similarities
were searched and molecular docking was performed. Lipinski rules were
used to discard compounds that did not meet the desired characteristics.
The researchers obtained a secondary library containing compounds that
showed optimal interaction with the T. vaginalis TvMP50 active site,
followed by a library containing scaffolds and new molecular entities or
chimeras. The best chimera presented a thermodynamically better value
than metronidazole. The next step is to synthesize or acquire the
compounds housed in this specialized chemical library against T.
vaginalis TvMP50 for the experimental phase.

\hypertarget{conclusion}{%
\subsubsection{Conclusion}\label{conclusion}}

We conclude that using chemoinformatics tools in a data-driven approach
allowed us to assemble a database of molecules to design a novel chimera
ELIE that may possess potential activity against TvMP50 of T. vaginalis
and that could be synthesized to validate experimentally its properties.

\end{document}
